CYYNF Stock - Cynata Therapeutics Limited
Unlock GoAI Insights for CYYNF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.89M | $2.32M | $1.65M | $7.77M | $1.55M |
| Gross Profit | $1.89M | $2.03M | $1.37M | $7.49M | $1.27M |
| Gross Margin | 100.0% | 87.9% | 83.1% | 96.4% | 81.9% |
| Operating Income | $-8,124,003 | $-8,807,923 | $-12,999,581 | $-4,287,247 | $-5,807,202 |
| Net Income | $-9,390,586 | $-9,744,709 | $-14,277,495 | $-5,445,172 | $-7,689,683 |
| Net Margin | -498.1% | -420.8% | -863.0% | -70.1% | -497.4% |
| EPS | $-0.05 | $-0.05 | $-0.10 | $-0.04 | $-0.06 |
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Visit WebsiteEarnings History & Surprises
CYYNFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q1 2025 | Feb 27, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 25, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 8, 2024 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.03 | — | — |
Q2 2020 | Jun 30, 2020 | $-0.03 | $-0.01 | +75.1% | ✓ BEAT |
Q4 2019 | Dec 30, 2019 | $-0.03 | $-0.02 | +37.7% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | — | $-0.04 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.02 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.02 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.02 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.03 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.01 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.03 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about CYYNF
What is CYYNF's current stock price?
What is the analyst price target for CYYNF?
What sector is Cynata Therapeutics Limited in?
What is CYYNF's market cap?
Does CYYNF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CYYNF for comparison